Publications

Inhibition of FGFR3-BAIAP2L1 fusion kinase oncogenic potential by CH5183284/Debio 1347, a compound that inhibits FGFR3 kinase activity constitutively activated by…

Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care…

FGFR genetic alterations as a potential predictor of the sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor with a novel…

Activity of IAP antagonist Debio 1143 as a monotherapy and in combination with standard of care agents in models of…

A simplified and Reliable Capillary Microsampling Procedure to Support Preclinical Regulatory Studies in Rodents

A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung…

Preclinical rationale for combining the Smac-mimetic Debio 1143 with concurrent chemioradiotherapy in LA-SCCHN

A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with Standard…

The cyclophilin inhibitor alisporivir prevents hepatitis C virus–mediated mitochondrial dysfunction